Alkermes plc is a global biopharmaceutical company focused on developing, manufacturing, and commercializing medicines for central nervous system disorders and other serious conditions. Its current portfolio includes treatments for schizophrenia, bipolar I disorder, alcohol dependence, opioid dependence, and narcolepsy-related symptoms, with products such as ARISTADA, ARISTADA INITIO, VIVITROL, LYBALVI, and LUMRYZ. The company works across research, clinical development, and product commercialization, using its drug formulation and delivery capabilities to support therapies designed for complex and chronic illnesses. Alkermes plc serves patients, healthcare providers, and healthcare systems in the United States, Ireland, and international markets. Founded in 1987 and headquartered in Dublin, Ireland, the company holds a notable position in the neuroscience-focused biopharmaceutical sector.
WebsiteConnaught House
Dublin, D04 C5Y6
Ireland
Alkermes plc (NASDAQ:ALKS) reported on September 21 that adults receiving the investigational oral drug ALKS 7290 showed improved symptoms of attention-deficit hyperactivity disorder (ADHD). After 14 days, median reductions on the Adult ADHD Investigator Symptom Rating Scale were 14 points at a total daily dose of 20 mg and 19 points at 50 mg. Both […]
In September 2026, Alkermes plc reported positive topline results from a phase 1b proof-of-concept study of ALKS 7290, an investigational orexin 2 receptor agonist, which showed clinically meaningful, dose-dependent improvements in adult ADHD symptoms over 14 days with a generally well-tolerated safety profile. These data represent the first clinical evidence of an orexin receptor agonist’s effects in ADHD, potentially widening Alkermes’ orexin franchise beyond sleep disorders and other...
ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.
Investors talking about ALKS also mention
| # | Name | Attention |
|---|---|---|
| 1 | Agios Pharmaceuticals, Inc.AGIO | 0%0 |
| 2 | BioMarin Pharmaceutical IncBMRN | 0%+0 |
| 3 | Jazz Pharmaceuticals plcJAZZ | 0%0 |
| 4 | Ironwood Pharmaceuticals, Inc. Class A Common StockIRWD | 0%new |
| 5 | Ionis Pharmaceuticals, Inc.IONS | 0%new |
| 6 | Acadia Pharmaceuticals Inc.ACAD | 0%+0 |
| 7 | Alnylam Pharmaceuticals, Inc.ALNY | 0%0 |
| 8 | Incyte Corp.INCY | 0%new |
| 9 | Biogen IncBIIB | 0%-0.01 |
| 10 | Amgen Inc.AMGN | 0.01%+0 |
What share of all stock conversation is about ALKS?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% +0 | 0% +0 | 0% +0 |
Of the messages about ALKS that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | 100% | 85.71% -14.29 | 90.1% +6.42 | ||
| Bearish | — | 0% | 14.29% +14.29 | 9.9% -6.42 |
Of the messages about ALKS that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | 81.82% | 66.67% | 21.23% | ||
| Technical Analysis | — | 0% | 16.67% | 3.99% | ||
| Analysts | — | 18.18% | 16.67% | 2.3% | ||
| Earnings | — | 0% | 0% | 0.5% | ||
| Controversies | — | 0% | 0% | 0.77% | ||
| Macro | — | 0% | 0% | 71.23% |
Of the messages about ALKS, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | — | 81.03% | 40.32% | 26.78% | ||
| Newcomers | — | 18.97% | 59.68% | 73.22% |